TMS Co., Ltd Logo

TMS Co., Ltd

Develops small molecule drugs from natural compounds for the global pharmaceutical market.

4891 | T

Overview

Corporate Details

ISIN(s):
JP3544960002
LEI:
Country:
Japan
Address:
府中市府中町一丁目9番地京王府中1丁目ビル11階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TMS Co., Ltd. is a biotechnology company engaged in the research, development, manufacture, and sale of pharmaceuticals, quasi-drugs, drug substances, and medical devices. The company focuses on developing small molecule drug candidates derived from natural compound libraries, collaborating with academic institutions to bridge scientific discoveries with the global pharmaceutical market. Its research includes the development of SMTPs (Small Molecule Therapeutic Products), which have shown potential in promoting thrombolysis, suppressing inflammation, and providing antioxidation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 08:41
Report Publication Announcement
確認書
Japanese 7.9 KB
2025-10-15 08:40
Interim Report
半期報告書-第22期(2025/03/01-2025/12/31)
Japanese 212.5 KB
2025-05-30 03:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.5 KB
2025-05-30 03:18
Registration Form
確認書
Japanese 7.9 KB
2025-05-30 03:17
Governance Information
内部統制報告書-第21期(2024/03/01-2025/02/28)
Japanese 21.1 KB
2025-05-30 03:15
Annual Report
有価証券報告書-第21期(2024/03/01-2025/02/28)
Japanese 2.9 MB
2025-04-09 09:05
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-03-14 07:58
Registration Form
有価証券届出書(組込方式)
Japanese 407.4 KB
2025-02-28 07:37
Legal Proceedings Report
臨時報告書
Japanese 18.5 KB
2025-02-06 09:01
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2024-10-15 08:18
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-10-15 08:15
Interim Report
半期報告書-第21期(2024/03/01-2025/02/28)
Japanese 176.1 KB
2024-07-12 08:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-07-12 08:12
Quarterly Report
四半期報告書-第21期第1四半期(2024/03/01-2024/05/31)
Japanese 125.8 KB
2024-05-29 03:27
Registration Form
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all TMS Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TMS Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TMS Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America ARMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.